Obseva (NASDAQ:OBSV)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Monday, Marketbeat Ratings reports. They currently have a $36.00 target price on the stock, down from their prior target price of $44.00.
Several other research firms have also recently issued reports on OBSV. Credit Suisse Group cut shares of Obseva from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $16.00 to $4.00 in a research note on Friday, November 8th. Royal Bank of Canada reissued a “buy” rating on shares of Obseva in a research report on Sunday, August 11th. BidaskClub raised shares of Obseva from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 30th. Zacks Investment Research upgraded shares of Obseva from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Finally, Wedbush reaffirmed a “buy” rating and issued a $38.00 target price on shares of Obseva in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $22.75.
OBSV opened at $4.52 on Monday. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.38. The firm has a market cap of $196.02 million, a P/E ratio of -2.37 and a beta of 0.59. Obseva has a 52 week low of $2.37 and a 52 week high of $15.93. The business’s fifty day simple moving average is $5.40 and its 200 day simple moving average is $8.92.
Obseva (NASDAQ:OBSV) last announced its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.19. As a group, equities analysts expect that Obseva will post -2.77 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC lifted its position in Obseva by 263.6% during the second quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after buying an additional 2,372 shares during the period. Morgan Stanley grew its holdings in Obseva by 358.6% in the 2nd quarter. Morgan Stanley now owns 3,100 shares of the company’s stock valued at $35,000 after buying an additional 2,424 shares during the period. Capital Investment Advisory Services LLC acquired a new position in shares of Obseva during the 2nd quarter valued at about $40,000. Renaissance Technologies LLC increased its stake in shares of Obseva by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock valued at $900,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Wedbush Securities Inc. increased its stake in shares of Obseva by 54.2% during the 3rd quarter. Wedbush Securities Inc. now owns 40,108 shares of the company’s stock valued at $334,000 after acquiring an additional 14,100 shares during the last quarter. Hedge funds and other institutional investors own 61.47% of the company’s stock.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Story: What is a Candlestick Chart?
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.